Trials / Completed
CompletedNCT03931954
Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
PREPARE STUDY: PRevalence of the Eosinophilic Phenotype Among SeveRE Asthma Patients in AstraZeneca International Region. A Multinational, Cross-Sectional, Multicenter Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 794 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this cross-sectional, multicenter study is to determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients who attend to sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and asthma control, will also be studied.
Detailed description
To determine the prevalence of an eosinophilic phenotype of blood eosinophil count ≥ 300 cells/mm3 among severe asthma patients attending their routine clinical visit at sites specialized in the management of severe asthma in several countries in the AstraZeneca International Region. The prevalence of an atopic phenotype and the status of asthma control, will also be studied. It is expected that this study will contribute to the understanding of severe asthma, ultimately helping to inform therapeutic decisions and addressing patients' needs.
Conditions
Timeline
- Start date
- 2019-05-15
- Primary completion
- 2020-11-26
- Completion
- 2020-11-26
- First posted
- 2019-04-30
- Last updated
- 2021-01-29
Locations
18 sites across 6 countries: Argentina, Chile, Colombia, Costa Rica, Mexico, Saudi Arabia
Source: ClinicalTrials.gov record NCT03931954. Inclusion in this directory is not an endorsement.